Antihypertensive medication and quality of life - Silent treatment of a silent killer?

被引:35
作者
Bremner, AD [1 ]
机构
[1] Rutherglen Hlth Ctr, Glasgow G73 2PQ, Lanark, Scotland
关键词
angiotensin-receptor blocker; compliance; hypertension; quality of life; sexual function;
D O I
10.1023/A:1021790112182
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertension is one of the major killers in the modern world and one of the great ironies of the disease is that it has little or no immediate effect on affected individuals' quality of life (QOL). This makes treatment very difficult, as most medications will affect QOL negatively, either through side effects or through the change in lifestyle associated with chronic drug regimens. This review describes some of the conceptual background for QOL measurements and looks at the effects on QOL of different antihypertensive treatments available today. The latest addition to the range of antihypertensive drugs, angiotensin II-receptor blockers, may be a significant step forward in treatment, as their ease of dosing and excellent tolerability minimise negative effects on patients while their possible benefits on factors such as sexual function may even improve QOL in hypertensive patients.
引用
收藏
页码:353 / 364
页数:12
相关论文
共 131 条
[51]   Randomised trial of old and new antihypertensive drugs in elderly patients:: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study [J].
Hansson, L ;
Lindholm, LH ;
Ekbom, T ;
Dahlöf, B ;
Lanke, J ;
Scherstén, B ;
Wester, PO ;
Hedner, T ;
de Faire, U .
LANCET, 1999, 354 (9192) :1751-1756
[52]  
Hansson L, 2002, INT J CLIN PRACT, V56, P191
[53]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[54]   Felodipine/Metoprolol - A review of the fixed dose controlled release formulation in the management of essential hypertension [J].
Haria, M ;
Plosker, GL ;
Markham, A .
DRUGS, 2000, 59 (01) :141-157
[55]   A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension [J].
Hedner, T ;
Oparil, S ;
Rasmussen, K ;
Rapelli, A ;
Gatlin, M ;
Kobi, P ;
Sullivan, J ;
Oddou-Stock, P .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) :414-417
[56]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide [J].
Hegner, G ;
Faust, G ;
Freytag, F ;
Meilenbrock, S ;
Sullivan, J ;
Bodin, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (03) :173-177
[57]  
HENNESSY CH, 1994, PUBLIC HEALTH REP, V109, P665
[58]   SEXUAL DYSFUNCTION WITH AGING AND SYSTEMIC HYPERTENSION [J].
HSUEH, WA .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 61 (16) :H18-H23
[59]  
HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185
[60]   Self-rated health and mortality: A review of twenty-seven community studies [J].
Idler, EL ;
Benyamini, Y .
JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 1997, 38 (01) :21-37